Mineralys Therapeutics, Inc.
NasdaqGS MLYS
Mineralys Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00
Mineralys Therapeutics, Inc. Revenue Per Share is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
-
Mineralys Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00.
Key data
| Date | Revenue Per Share | Dividend Per Share | Free Cash Flow Per Share | Return on Assets (ROA) |
|---|
Market news
Loading...
NasdaqGS: MLYS
| CEO | Mr. Jon Congleton |
| IPO Date | Feb. 10, 2023 |
| Location | United States |
| Headquarters | 150 N. Radnor Chester Rd. |
| Employees | 28 |
| Sector | Health Care |
| Industries | |
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email